Identifying mutations in relapsed pediatric neuroblastoma may lead to better treatment options
the ONA take:
According to a new study published today in the journal Nature Genetics, researchers from various sites around the world have found that the majority of pediatric patients with relapsed neuroblastoma studied harbored mutations that promoted RAS-MAPK pathway signaling. Increased signaling in this pathway results in the progression of neuroblastoma.
"Our greater understanding of mutations on a crucial biological pathway offers prospects of acting on these pathways for direct benefit to children with this aggressive form of neuroblastoma," said senior author John M. Maris, M.D., a pediatric oncologist at The Children's Hospital of Philadelphia.
A class of drugs known as MEK inhibitors have demonstrated activity against this signaling pathway, suggesting that MEK inhibitors may benefit relapsed patients who possess mutations on the RAS-MAPK pathway.
Neuroblastoma is a solid tumor of the peripheral system that often grows in the chest or abdomen. It is the most common type of cancer in infants and is known for a high mortality rate in children. Most patients initially respond to chemotherapy, but many relapse and die from the disease.
Majority of pediatric patients with relapsed neuroblastoma studied harbored mutations that promoted RAS-MAPK pathway signaling.
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- High Symptom Burden With Polycythemia Vera Linked to QoL Impairment
- Bioimpedence Spectroscopy Improves Early Detection of Breast Cancer-Related Lymphedema in At-Risk Patients
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- MRD Negativity Associated With Prolonged Survival in Myeloma
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Study Assesses Efficacy of Ramucirumab in HCC by Child-Pugh Score
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Patient Navigation Reduces Delays in Diagnostic Resolution
- Fee-for-service Medicare Plans Linked to Improved Care During Last Year of Life
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|